Core Viewpoint - Conagra Brands (CAG) is expected to report a decline in quarterly earnings and revenues, with analysts adjusting their estimates downward over the past month [1][2]. Financial Performance - Quarterly earnings are predicted to be $0.59 per share, a decrease of 3.3% year-over-year [1]. - Revenues are forecasted at $2.85 billion, reflecting a year-over-year decrease of 1.8% [1]. Analyst Revisions - The consensus EPS estimate has been adjusted downward by 2% over the past 30 days, indicating a reassessment by covering analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and stock price performance [3]. Sales Projections - 'Sales- Grocery & Snacks' are expected to reach $1.18 billion, showing a year-over-year increase of 0.7% [5]. - 'Sales- Foodservice' is forecasted at $282.84 million, indicating a decline of 2.9% from the prior year [5]. - 'Sales- International' is projected to be $228.22 million, reflecting a significant decrease of 14.5% year-over-year [5]. Operating Profit Estimates - 'Adjusted Operating Profit (loss)- Grocery & Snacks' is estimated at $256.07 million, slightly up from $255.40 million a year ago [8]. - 'Adjusted Operating Profit (loss)- Refrigerated & Frozen' is projected at $171.73 million, down from $189.70 million in the same quarter last year [8]. - 'Adjusted Operating Profit (loss)- Foodservice' is expected to be $38.03 million, down from $39.70 million year-over-year [9]. - 'Adjusted Operating Profit (loss)- International' is estimated at $29.74 million, slightly up from $28.90 million a year ago [9]. Stock Performance - Over the past month, shares of Conagra Brands have declined by 5.7%, contrasting with a 5.2% increase in the Zacks S&P 500 composite [10]. - Conagra Brands currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance in the near future [10].

Core Insights - McKesson reported revenue of $90.82 billion for the quarter ended March 2025, reflecting a 19% increase year-over-year, with EPS at $10.12 compared to $6.18 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $93.7 billion by 3.08%, while the EPS exceeded the consensus estimate of $9.81 by 3.16% [1] Revenue Breakdown - U.S. Pharmaceutical revenue was $83.17 billion, a 20.9% increase year-over-year, but below the average estimate of $85.79 billion [4] - Prescription Technology Solutions revenue reached $1.34 billion, up 13.5% year-over-year, slightly below the average estimate of $1.36 billion [4] - International revenue was $3.46 billion, showing a year-over-year decline of 2.5%, compared to the average estimate of $3.55 billion [4] - Medical-Surgical Solutions revenue was $2.85 billion, a 0.6% increase year-over-year, exceeding the average estimate of $2.79 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for U.S. Pharmaceutical was $1.05 billion, matching the average estimate [4] - Adjusted Operating Profit for International was $102 million, surpassing the average estimate of $96.42 million [4] - Adjusted Operating Profit for Corporate was -$165 million, slightly worse than the average estimate of -$160.18 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $285 million, exceeding the average estimate of $267.80 million [4] - Adjusted Operating Profit for Medical-Surgical Solutions was $285 million, slightly above the average estimate of $283.33 million [4] Stock Performance - McKesson's shares returned +7.5% over the past month, underperforming compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - H&R Block (HRB) is expected to report quarterly earnings of $5.12 per share, reflecting a year-over-year increase of 3.6% [1] - Anticipated revenues for the quarter are projected at $2.25 billion, which represents a 2.8% increase compared to the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating analysts' reassessment of their projections [1] Revenue Estimates - Analysts predict 'Revenues- U.S. assisted tax preparation' to be $1.60 billion, showing a year-over-year change of +4.5% [4] - 'Revenues- U.S. royalties' are expected to be $133.04 million, indicating a decline of -6.3% from the previous year [4] - 'Revenues- U.S. DIY tax preparation' is estimated to reach $202.19 million, reflecting a +1.8% change year-over-year [4] International and Other Revenue Projections - 'Revenues- International' are forecasted at $70.58 million, suggesting a +3.4% change year-over-year [5] - 'Revenues- Refund Transfers' are expected to be $116.00 million, indicating a -2.5% change from the prior year [5] - 'Revenues- Tax Identity Shield' is projected at $7.21 million, reflecting a -4.3% change year-over-year [5] Additional Revenue Insights - 'Revenues- Peace of Mind Extended Service Plan' is expected to be $16.71 million, indicating a -0.6% change [6] - 'Revenues- Interest and fee income on Emerald Advance' is projected at $19.12 million, suggesting a -9.7% change year-over-year [6] - 'Revenues- Other' is estimated to reach $12.98 million, reflecting a +7.6% change from the previous year [6] Performance and Market Position - The consensus estimate for 'Revenues- Wave' stands at $26.30 million, indicating a +11.5% change year-over-year [7] - 'Revenues- Emerald Card and Spruce' are expected to be $37.56 million, reflecting a -8.8% change from the prior year [7] - H&R Block shares have returned +12.5% over the past month, outperforming the Zacks S&P 500 composite's +11.5% change [7]